- Dimebolin
-
- $35.00 / 1mg
-
2025-04-28
- CAS:3613-73-8
- Min. Order:
- Purity: 99.92%
- Supply Ability: 10g
- dimebolin
-
- $1.10 / 1g
-
2021-10-12
- CAS:3613-73-8
- Min. Order: 1g
- Purity: 99.00%
- Supply Ability: 100 Tons Min
- Latrepirdine
-
- $1.00 / 1g
-
2020-01-13
- CAS:3613-73-8
- Min. Order: 1g
- Purity: 95-99%
- Supply Ability: 1ton
|
| | dimebolin Basic information |
| Product Name: | dimebolin | | Synonyms: | dimebolin;2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole;2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole;Dimeboline;Dimebone;Preparation-84;dimebon;2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-1H-pyrido[4,3-b]indole | | CAS: | 3613-73-8 | | MF: | C21H25N3 | | MW: | 319.44 | | EINECS: | 638-815-4 | | Product Categories: | | | Mol File: | 3613-73-8.mol |  |
| | dimebolin Chemical Properties |
| Melting point | 115-116 °C | | Boiling point | 448.46°C (rough estimate) | | density | 1.13 | | refractive index | 1.6380 (estimate) | | storage temp. | Store at -20°C | | solubility | ≤30mg/ml in ethanol;1mg/ml in DMSO;3mg/ml in dimethyl formamide | | form | crystalline solid | | pka | 9.05±0.20(Predicted) | | CAS DataBase Reference | 3613-73-8 |
| | dimebolin Usage And Synthesis |
| Uses | Non-steroidal anti-inflammatory with analgesic and antipyretic effects | | Definition | ChEBI: Latrepirdine is a member of methylpyridines and a pyridoindole. It has a role as a geroprotector. | | Biological Activity | dimebolin is an orally-available antihistamine drug with a long history of clinical use in russia [1][2][3][4].dimebolin has been proposed to be useful for treating neurodegenerative disorders, including alzheimer's disease (ad) and huntington's disease (hd). dimebon might exhibit efficacy by blocking nmda receptors or voltage-gated ca2+ channels and by preventing mitochondrial permeability pore transition [3].dimebolin is an orally-available antihistamine drug. dimebon improved survival of cerebellar granule cells during long-term incubation with aβ25-35. dimebolin also blocked potential-dependent ca(2+) entry into neurons by about 20% by blocking l-type ca(2+) channels [4]. in the cerebellum cell culture, dimebolin protected neurons against the neurotoxic action of aβ25-35 with ec50 value of 25 μm. on isolated rat ileum intestine, dimebolin displayed ca2+-blocking properties with ic50 value of 57 μm. dimebon also exhibited anticholinesterase activity with ic50 values of 7.9 μm and 42 μm for butyryl-choline esterase and acetylcholine esterase, respectively [5].in rats treated with the neurotoxin af64a, dimebolin exhibited cognition and memory-enhancing properties. in mice, dimebolin prevented nmda-induced seizures with ec50 value of 42 ± 6 mg/kg [5]. | | in vivo | Latrepirdine treatment of TgCRND8 transgenic mice is associated with improved learning behavior and with a reduction in accumulation of Aβ42 and α-synuclein. Male, 90-day-old TgCRND8 mice or their wild-type littermates (nTg) receive 31 consecutive once daily i.p. injections of either 3.5 mg/kg Latrepirdine or 0.9% saline (vehicle). At the culmination of treatment, mice are tested for cued and contextual fear conditioning using a paradigm that has been widely accepted for evaluating learning and memory deficits in APP transgenic mice. A significant increase in cued memory only among Latrepirdine-versus vehicle-treated TgCRND8 mice (p=0.01) is observed. A weak, non-significant trend toward an improvement in contextual memory among Latrepirdine-versus vehicle-treated mice (p=0.099) is also observed[1]. | | references | [1]. lermontova nn, lukoyanov nv, serkova tp, et al. dimebon improves learning in animals with experimental alzheimer's disease. bull exp biol med. 2000 jun;129(6):544-6.
[2]. doody rs, gavrilova si, sano m, et al. effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate alzheimer's disease: a randomised, double-blind, placebo-controlled study. lancet. 2008 jul 19;372(9634):207-15.
[3]. wu j, li q, bezprozvanny i. evaluation of dimebon in cellular model of huntington's disease. mol neurodegener. 2008 oct 21;3:15.
[4]. lermontova nn, redkozubov ae, shevtsova ef, et al. dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block l-type ca(2+) channels. bull exp biol med. 2001 nov;132(5):1079-83.
[5]. bachurin s, bukatina e, lermontova n, et al. antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. ann n y acad sci. 2001 jun;939:425-35. |
| | dimebolin Preparation Products And Raw materials |
|